Cargando…

Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis

Despite the same manufacturer, the same drotrecogin alfa activated dose, and the same placebo-controlled design, the negative result from the PROWESS-SHOCK trial contradicted the survival benefit observed in the PROWESS trial. We hypothesize that the different results were due to factors other than...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalil, Andre C, Florescu, Diana F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706817/ https://www.ncbi.nlm.nih.gov/pubmed/23826709 http://dx.doi.org/10.1186/cc12752

Ejemplares similares

Statistical analysis plan of PROWESS SHOCK study
por: Thompson, B. Taylor, et al.
Publicado: (2010)

CERN’s prowess in nothingness: Vacuum technology
por: Chiggiato, Paolo
Publicado: (2018)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Facial Attractiveness as a Function of Athletic Prowess
por: Bagozzi, Richard P., et al.
Publicado: (2018)

Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial
por: Póvoa, Pedro, et al.
Publicado: (2015)

Updates on role of human recombinant activated protein C in patients with sepsis and severe sepsis: Changed scenario after PROWESS SHOCK trial
por: Shukla, Aparna
Publicado: (2012)

The fully integrated engineer: combining technical ability and leadership prowess
por: Cerri, Steven T
Publicado: (2016)

The Prowess of Andrographolide as a Natural Weapon in the War against Cancer
por: Farooqi, Ammad Ahmad, et al.
Publicado: (2020)

Heparin Prowess: Favorable Vascular–Immune Reprogramming in Pancreatic Cancer
por: Korc, Murray
Publicado: (2023)

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
por: Laterre, Pierre-François, et al.
Publicado: (2008)

A biopolymer-like metal enabled hybrid material with exceptional mechanical prowess
por: Zhang, Junsong, et al.
Publicado: (2015)

The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Vincent, J, et al.
Publicado: (2004)

Proof of surgical publication prowess: prospective observational study of factors associated with surrogate markers of academic reach
por: Robinson, D. B. T., et al.
Publicado: (2020)

Enhanced Gas Separation Prowess Using Functionalized Lignin-Free Lignocellulosic Biomass/Polysulfone Composite Membranes
por: Amusa, Abiodun Abdulhameed, et al.
Publicado: (2021)

The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Beale, R, et al.
Publicado: (2004)

Is cytomegalovirus reactivation increasing the mortality of patients with severe sepsis?
por: Kalil, Andre C, et al.
Publicado: (2011)

Positive geographic correlation between soldiers’ weapon size and defensive prowess in a eusocial aphid, Ceratovacuna japonica
por: Hattori, Mitsuru, et al.
Publicado: (2022)

Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Vincent, J, et al.
Publicado: (2004)

The complex link between influenza and severe sepsis
por: Florescu, Diana F, et al.
Publicado: (2014)

When metabolic prowess is too much of a good thing: how carbon catabolite repression and metabolic versatility impede production of esterified α,ω-diols in Pseudomonas putida KT2440
por: Lu, Chunzhe, et al.
Publicado: (2021)

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
por: Osumi, Hiroki, et al.
Publicado: (2022)

2240. Can Antibiotic Duration Be Reduced by the Sequential Use of Procalcitonin and Endotoxin in Patients with Sepsis? A Prospective Double-Blind Clinical Trial
por: Kalil, Andre C, et al.
Publicado: (2019)

The outcome of patients presenting to the emergency department with severe sepsis or septic shock
por: Rivers, Emanuel
Publicado: (2006)

Systematic screening is essential for early diagnosis of severe sepsis and septic shock
por: Westphal, Glauco Adrieno, et al.
Publicado: (2015)

Predicting treatment failure in severe sepsis and septic shock: looking for the Holy Grail
por: Ruiz-Rodríguez, Juan Carlos, et al.
Publicado: (2013)

Cortisol replacement for severe sepsis and septic shock: what should I do?
por: Annane, Djillali
Publicado: (2002)

Should microcirculation monitoring be used to guide fluid resuscitation in severe sepsis and septic shock?
por: Ospina-Tascón, Gustavo A., et al.
Publicado: (2015)

Should heparin-binding protein levels be routinely monitored in patients with severe sepsis and septic shock?
por: Holub, Michal, et al.
Publicado: (2012)

The kinetics of T regulatory cells in shock: beyond sepsis
por: Christaki, Eirini, et al.
Publicado: (2010)

Immunostimulation using granulocyte- and granulocyte-macrophage colony stimulating factor in patients with severe sepsis and septic shock
por: Schefold, Joerg C
Publicado: (2011)

The International Sepsis Forum's controversies in sepsis: corticosteroids should be used to treat septic shock
por: Goodman, Sergey, et al.
Publicado: (2002)

The staging of sepsis: understanding heterogeneity in treatment efficacy
por: Marshall, John C
Publicado: (2005)

The International Sepsis Forum's controversies in sepsis: corticosteroids should not be routinely used to treat septic shock
por: Bernard, Gordon
Publicado: (2002)

Why Are Clinicians Not Embracing the Results from Pivotal Clinical Trials in Severe Sepsis? A Bayesian Analysis
por: Kalil, Andre C., et al.
Publicado: (2008)

“Early goal-directed therapy” versus “Early” and “goal-directed” therapy for severe sepsis and septic shock: Time to rationalize
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Sex and severe sepsis
por: Guidet, Bertrand, et al.
Publicado: (2013)

The original sins of clinical trials with intravenous immunoglobulins in sepsis
por: Almansa, Raquel, et al.
Publicado: (2015)

Repurposed drugs for COVID-19: threshold and proof requirements for trials
por: Paul, Mical, et al.
Publicado: (2021)

The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is norepinephrine rather than dopamine
por: Sharma, Vinay K, et al.
Publicado: (2003)

The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is dopamine rather than norepinephrine
por: Vincent, Jean-Louis, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_ednlkkf63kr67ekbeim869ane6